Emvena Therapeutics, a Philadelphia-based biotechnology startup developing placenta-targeted mRNA medicines, has received seed financing from the Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund). The investment marks the fund’s first company launch and financing. The amount was not disclosed.
The funding will support the development of Emvena’s lead therapeutic program toward investigational new drug (IND)-enabling studies and the expansion of its technology platform into additional maternal and fetal health indications.
Founded in 2026, Emvena Therapeutics was established to commercialize research originating from the laboratory of Michael J. Mitchell at the University of Pennsylvania. Its co-founders include Mitchell, Kelsey L. Swingle, Hannah Safford, Allison August and Young T. Kwon, who serves as Chief Executive Officer and Executive Chair.
Emvena is developing messenger RNA (mRNA) medicines that use specialized lipid nanoparticles (LNPs) to deliver therapeutic molecules preferentially to the placenta. Its lead program focuses on preeclampsia, a serious pregnancy complication associated with elevated blood pressure and potential risks to maternal and fetal health.
The company’s technology builds on research published in Nature, which demonstrated that placenta-targeted lipid nanoparticles carrying mRNA encoding vascular endothelial growth factor (VEGF) could reduce maternal hypertension and improve certain placental and fetal health measures in mouse models of preeclampsia. The findings are preclinical, and the treatment’s safety and effectiveness in humans have not been established.
The investment comes from the $50 million PxB Fund, established by the University of Pennsylvania, BioNTech SE and Osage University Partners. Managed by Osage University Partners, the fund invests in early-stage life sciences companies developing therapeutics, diagnostics, research tools and biotechnology platforms originating from Penn research.

